Work

Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit

Year: 2024

Type: review

Source: Ageing Research Reviews

DOI: 10.1016/j.arr.2024.102348

Authors: Poul F. Høilund-Carlsen, Abass Alavi, Jorge R. Barrio, Rudolph J. Castellani, Tommaso Costa, Karl Herrup, Kasper P. Kepp, Rachael L. Neve, George Perry, Mona-Elisabeth Revheim, Nikolaos K. Robakis, Stefano L. Sensi, Bryce Vissel

Institutions: University of Southern Denmark, Odense University Hospital, Hospital of the University of Pennsylvania, University of Pennsylvania, University of California, Los Angeles, Northwestern University, Ospedale Koelliker, University of Turin, University of Pittsburgh, Technical University of Denmark, Massachusetts General Hospital, The University of Texas at San Antonio, Oslo University Hospital, University of Oslo, Icahn School of Medicine at Mount Sinai, University of Chieti-Pescara, UNSW Sydney, St Vincent's Hospital Sydney

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Ministero della Salute

OpenAlex ID: W4399258296

FWCI: 3.062

Cites: 34

Cited by: 40

Related to: 10